Uropharmacology: current and future strategies in the treatment of erectile dysfunction and benign prostate hyperplasia.
Because of the increasing percentage of the world male population suffering from erectile dysfunction (ED) and benign prostate syndrome (BPS), there is a need for new and innovative therapeutic approaches. Pharmacotherapy is an avenue presently being followed in the treatment of both these syndromes. A profound change in the therapy of ED has been obtained through use of the selective phosphodiesterase inhibitor sildenafil. The incidence of surgical intervention in BPS has been reduced by the introduction of uroselective alpha1-receptor antagonists and the new 5alpha-reductase inhibitors (such as finasteride, dutasteride). The investigation of mechanisms in CXC chemokine expression also offers new therapeutic possibilities in these diseases.
Engl
T
T
Department of Urology and Pediatric Urology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany. Engl@em.uni-frankfurt.de
Beecken
W D
WD
Wolfram
M
M
Jonas
D
D
Blaheta
R
R
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D019743:Chemokines, CXC / Q000096:biosynthesis / Q000627:therapeutic use; D004358:Drug Therapy / Q000639:trends*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D008517:Phytotherapy; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D019743:Chemokines, CXC; D010726:Phosphodiesterase Inhibitors